Dissecting the pathogenesis of HIV-TB Immune reconstitution inflammatory syndrome
剖析 HIV-TB 免疫重建炎症综合征的发病机制
基本信息
- 批准号:10667439
- 负责人:
- 金额:$ 75.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-17 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse effectsAftercareAnimal ModelAnimalsAnti-Retroviral AgentsAntitubercular AgentsAutopsyBacteriaBiologicalBloodCD4 Lymphocyte CountCellsCessation of lifeCharacteristicsClinicalCollaborationsComplexCountryDataDevelopmentDiseaseDisease modelEarly treatmentEventGoalsGranulomaHIVHIV InfectionsHIV/TBHealthcareHeterogeneityHospitalizationHumanImageImmuneImmune responseImmune systemImmunologicsImmunologyImprove AccessIncidenceInfectionInflammationInflammatoryKnowledgeLungMeasuresMedical ResearchMissionModalityModelingMolecularMorbidity - disease rateMycobacterium tuberculosisNational Institute of Allergy and Infectious DiseaseNaturePET/CT scanPathogenesisPathologyPatientsPersonsPharmaceutical PreparationsPharmacotherapyPlasmaPrednisonePreventionPrevention strategyProcessRecurrenceResearch InfrastructureResearch PersonnelResourcesRiskSIVSigns and SymptomsSiteSymptomsSyndromeTechnologyTherapeuticTimeTissuesTuberculosisUnited States National Institutes of HealthVaccinesVirusadaptive immune responseantiretroviral therapybiological heterogeneitybiomarker identificationclinical predictorsco-infectioncomparison controlglobal healthhigh riskhuman diseasehuman modelimmune functionimmune reconstitutionimprovedin vivo imaginginsightlymph nodesmortalitymortality risknew technologynonhuman primatepathogenpreventprogramspulmonary granulomaradiological imagingresponsesynergismtime intervaltooltuberculosis drugstuberculosis treatmentvirtual
项目摘要
Despite major advances in global health care, there were an estimated 1.5 millions deaths and 10 million new
cases of tuberculosis (TB) in 2018. Nearly 1 million people living with HIV developed tuberculosis (TB). Co-
infection with HIV and TB is associated with high morbidity and mortality and treatment with TB drugs and anti-
retroviral (ART) therapy is now universally available. TB drug treatment followed by ART improves long term
survival, particularly among those whose immune systems are severely suppressed from HIV infection. Signs
and symptoms of disease improve soon after treatment is started but, in many cases, disease can recur and
appear clinically worse as the immune system is being re-established from ART. This is known as TB-
associated Immune Reconstitution Inflammatory Syndrome (TB-IRIS) and is more common among patients
with severely suppressed immune systems before treatment and those who have a short time interval between
starting TB treatment and ART. Very little is known about how or why TB-IRIS occurs and how to best to treat
or even prevent it. We hypothesize that symptoms of TB-IRIS are driven by the dynamic interaction between
the immune system, Mycobacterium tuberculosis (Mtb, the bacteria that causes TB) and HIV deep within
infected tissues in the body such as the lung granuloma. Virtually nothing is known about what happens in the
tissues where both Mtb and HIV interact during TB-IRIS. This proposal will develop an animal model of TB-
IRIS by taking advantage of our pre-existing model of HIV-TB co-infection in which animals with SIV-Mtb co-
infection undergo TB drug treatment and ART just like humans. We will use sophisticated imaging,
immunology and microbiologic tools to better understand how and why TB-IRIS develops and what factors can
predict its emergence. Aim 1 will determine how often TB-IRIS occurs in this model and to what extent Mtb and
SIV remain in the tissues during treatment. We will also perform a detailed examination of the changes that
occur in the tissues but especially the lungs (granulomas) and lymph nodes through serial in vivo images to
better understand the events that lead to TB-IRIS and its predictors. In Aim 2, we will perform a detailed
examination of the immunologic events in the tissues and blood during TB-IRIS. Tissue specific (lung
granulomas and lymph nodes) immune responses will be correlated with the amount of Mtb bacteria and virus
with the imaging findings so that we can better understand the causes of TB-IRIS. Our short term goal is to
better understand the pathogenesis of TB-IRIS in this proposal and these findings will ultimately lead to better
treatment and prevention of TB-IRIS which is our long term goal.
尽管全球医疗保健取得了重大进展,但估计仍有150万人死亡,新增1000万人
2018年结核病病例数。近100万艾滋病毒携带者患上了结核病。共同--
感染艾滋病毒和结核病与高发病率和死亡率以及使用结核病药物和抗结核药物治疗有关
逆转录病毒(ART)疗法现在普遍可用。结核病药物治疗后抗逆转录病毒治疗可改善长期疗效
存活,特别是那些免疫系统受到严重抑制而不受艾滋病毒感染的人。标牌
疾病症状在治疗开始后不久就会改善,但在许多情况下,疾病可能会复发和
临床上看起来更糟,因为免疫系统正在通过抗逆转录病毒治疗重建。这就是众所周知的结核病-
相关免疫重建炎症综合征(TB-IRIS),在患者中更常见
治疗前免疫系统受到严重抑制的患者,以及
开始结核病治疗和抗逆转录病毒治疗。关于结核病-IRIS如何或为什么发生以及如何最好地治疗,人们知之甚少
或者甚至阻止它。我们假设TB-IRIS的症状是由两者之间的动态相互作用驱动的
免疫系统,结核分枝杆菌(结核分枝杆菌,引起结核病的细菌)和艾滋病毒
体内受感染的组织,如肺肉芽肿。几乎不知道发生了什么
结核分枝杆菌和艾滋病毒在结核病-IRIS期间相互作用的组织。这项提议将开发一种结核病的动物模型--
虹膜通过利用我们先前存在的艾滋病毒-结核病联合感染模型,在该模型中,携带SIV-MTB的动物共同-
与人类一样,感染者也要接受结核病药物治疗和抗逆转录病毒治疗。我们将使用复杂的成像技术,
免疫学和微生物学工具,以更好地了解结核病-IRIS是如何和为什么发生的,以及哪些因素可以
预测它的出现。目标1将确定结核病-IRIS在该模型中发生的频率以及结核分枝杆菌和
在治疗过程中,SIV仍留在组织中。我们还将对以下更改执行详细检查
发生在组织中,特别是肺(肉芽肿)和淋巴结通过一系列活体图像
更好地了解导致结核病-IRIS的事件及其预测因素。在目标2中,我们将执行详细的
TB-IRIS期间组织和血液中免疫事件的检测。组织特异性(肺
肉芽肿和淋巴结)免疫反应将与结核分枝杆菌和病毒的数量相关
结合影像表现,以便更好地了解TB-IRIS的病因。我们的短期目标是
在这项建议中,更好地理解结核病-IRIS的发病机制,这些发现最终将导致更好的
治疗和预防结核病-IRIS是我们的长期目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JoAnne L. Flynn其他文献
This information is current as Infection Mycobacterium tuberculosis during Antimicrobial Responses with Caseation Mediated − Early Host Immunity Control of Lesion Sterilization by Balancing Computational Modeling Predicts IL-10
此信息是当前的感染结核分枝杆菌在干酪介导的抗菌反应期间通过平衡计算模型预测 IL-10 进行病灶灭菌的早期宿主免疫控制
- DOI:
- 发表时间:
2014 - 期刊:
- 影响因子:0
- 作者:
Nicholas A. Cilfone;Christopher B Ford;Simeone Marino;Joshua T Mattila;H. Gideon;JoAnne L. Flynn;Denise E. Kirschner;J. Linderman - 通讯作者:
J. Linderman
Modeling pathogen and host: <em>in vitro</em>, <em>in vivo</em> and <em>in silico</em> models of latent <em>Mycobacterium tuberculosis</em> infection
- DOI:
10.1016/j.ddmod.2005.05.019 - 发表时间:
2005-06-01 - 期刊:
- 影响因子:
- 作者:
P. Ling Lin;Denise Kirschner;JoAnne L. Flynn - 通讯作者:
JoAnne L. Flynn
emIn silico/em identification and synthesis of a multi-drug loaded MOF for treating tuberculosis
- DOI:
10.1016/j.jconrel.2022.10.024 - 发表时间:
2022-12-01 - 期刊:
- 影响因子:11.500
- 作者:
Abhinav P. Acharya;Kutay B. Sezginel;Hannah P. Gideon;Ashlee C. Greene;Harrison D. Lawson;Sahil Inamdar;Ying Tang;Amy J. Fraser;Kush V. Patel;Chong Liu;Nathaniel L. Rosi;Stephen Y. Chan;JoAnne L. Flynn;Christopher E. Wilmer;Steven R. Little - 通讯作者:
Steven R. Little
This information is current as Infection in BALB / c Mice tuberculosis Mycobacterium the Control of Chronic The Chemokine Receptor CXCR 3 Attenuates
此信息当前为 BALB / c 小鼠结核分枝杆菌感染控制慢性趋化因子受体 CXCR 3 减弱
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
S. Chakravarty;Jiayong Xu;Bao Lu;Craig Gerard;JoAnne L. Flynn;John Chan - 通讯作者:
John Chan
SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues
SARS-CoV-2 受体 ACE2 是人气道上皮细胞中的干扰素刺激基因,富含组织中的特定细胞亚群
- DOI:
- 发表时间:
2020 - 期刊:
- 影响因子:0
- 作者:
Carly N Ziegler;Samuel J. Allon;Sarah K Nyquist;Ian M. Mbano;Vincent N Miao;Yuming Cao;Ashraf S. Yousif;Julia Bals;B. Hauser;J. Feldman;Christoph Muus;Marc H Wadsworth Ii;S. Kazer;T. Hughes;B. Doran;G. J. Gatter;Marko Vukovic;C. Tzouanas;F. Taliaferro;Zhiru Guo;Jennifer P. Wang;Daniel F Dwyer;K. Buchheit;Joshua A. Boyce;Nora A. Barrett;T. Laidlaw;Shaina L. Carroll;Lucrezia Colonna;V. Tkachev;Alison Yu;Henqi Betty Zheng;H. Gideon;Caylin G. Winchell;P. Lin;Bonnie Berger;A. Leslie;JoAnne L. Flynn;Sarah M Fortune;R. Finberg;Leslie S. Kean;Manuel Garber;Aaron Schmidt;D. Lingwood;A. Shalek;J. Ordovas;Hca Lung Biological Network - 通讯作者:
Hca Lung Biological Network
JoAnne L. Flynn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JoAnne L. Flynn', 18)}}的其他基金
Enhancing cytotoxic lymphocytes in a TB vaccine strategy
在结核病疫苗策略中增强细胞毒性淋巴细胞
- 批准号:
10462928 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
Enhancing cytotoxic lymphocytes in a TB vaccine strategy
在结核病疫苗策略中增强细胞毒性淋巴细胞
- 批准号:
10580073 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
Dissecting the pathogenesis of HIV-TB Immune reconstitution inflammatory syndrome
剖析 HIV-TB 免疫重建炎症综合征的发病机制
- 批准号:
10097199 - 财政年份:2020
- 资助金额:
$ 75.06万 - 项目类别:
Dissecting the pathogenesis of HIV-TB Immune reconstitution inflammatory syndrome
剖析 HIV-TB 免疫重建炎症综合征的发病机制
- 批准号:
10451735 - 财政年份:2020
- 资助金额:
$ 75.06万 - 项目类别:
Dissecting the pathogenesis of HIV-TB Immune reconstitution inflammatory syndrome
剖析 HIV-TB 免疫重建炎症综合征的发病机制
- 批准号:
10240712 - 财政年份:2020
- 资助金额:
$ 75.06万 - 项目类别:
Predicting protective T-cell responses in Tuberculosis using a systems biology approach
使用系统生物学方法预测结核病中的保护性 T 细胞反应
- 批准号:
9072491 - 财政年份:2016
- 资助金额:
$ 75.06万 - 项目类别:
The Effects of M. tuberculosisInfection on Lung Microbiome in Macaques
结核分枝杆菌感染对猕猴肺部微生物组的影响
- 批准号:
9018134 - 财政年份:2016
- 资助金额:
$ 75.06万 - 项目类别:
An adjuvant that promotes TH1/TH17 and CD8 T cells in a tuberculosis vaccine
一种在结核疫苗中促进 TH1/TH17 和 CD8 T 细胞的佐剂
- 批准号:
8607041 - 财政年份:2013
- 资助金额:
$ 75.06万 - 项目类别:
An adjuvant that promotes TH1/TH17 and CD8 T cells in a tuberculosis vaccine
一种在结核疫苗中促进 TH1/TH17 和 CD8 T 细胞的佐剂
- 批准号:
8994259 - 财政年份:2013
- 资助金额:
$ 75.06万 - 项目类别:
An adjuvant that promotes TH1/TH17 and CD8 T cells in a tuberculosis vaccine
一种在结核疫苗中促进 TH1/TH17 和 CD8 T 细胞的佐剂
- 批准号:
9208083 - 财政年份:2013
- 资助金额:
$ 75.06万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 75.06万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 75.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 75.06万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 75.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 75.06万 - 项目类别:
Discovery Grants Program - Individual